Skip to main content
. 2022 Sep 14;12:932156. doi: 10.3389/fonc.2022.932156

Figure 3.

Figure 3

In vivo distribution of PTX in tumor-bearing mice treated with PTX-NPs, PTX/NCTD-NPs, and PTX/NCTD-APRPG-NPs. The experimental mice were randomly divided into three groups (PTX-NP, PTX/NCTD-NP, and PTX/NCTD-APRPG-NP groups) and injected with PTX-NPs, PTX/NCTD-NPs, or PTX/NCTD-APRPG-NPs at the dosage of 10 mg/kg. The tissue distribution of PTX was detected at 0.5, 2, and 6 h following injection. Bar graphs show PTX concentrations in various organs (heart, liver, spleen, lung, kidney, and stomach) and tumor tissues at (A) 0.5 h, (B) 2 h, and (C) 6 h after injection; ###p < 0.001 vs. PTX-NPs; &p < 0.05, &&&p < 0.001 vs. PTX/NCTD-NPs. (D) In vivo imaging assay to visualize the distribution of PTX in tumor-bearing mice treated with PTX-NPs, PTX/NCTD-NPs, and PTX/NCTD-APRPG-NPs. At 2 h after injection, the tissue distributions of PTX in the three experimental groups were imaged on the Bruker Small Animal Optical Imaging System.